Naturally Inspired Molecules as Multifunctional Agents for Alzheimer’s Disease Treatment
Authors:
- Angela RampaAngela Rampa
- Andrea TarozziAndrea Tarozzi
- Francesca ManciniFMFrancesca Mancini
- Letizia PruccoliLPLetizia Pruccoli
- Rita Maria Concetta Di MartinoRMRita Maria Concetta Di Martino
- Silvia GobbiSGSilvia Gobbi
- Alessandra BisiAlessandra Bisi
- Angela De SimoneASAngela De Simone
- Francesco PalombaFPFrancesco Palomba
- Nelsi ZaccheroniNZNelsi Zaccheroni
- Federica BellutiFederica Belluti
Open Access
Abstract
Alzheimer’s disease (AD) has been defined as a multi-factorial disorder resulting from a complex array of networked cellular and molecular mechanisms. In particular, elevated levels of Aβ protein and its aggregation products in the presence of metal ions proved to be highly neurotoxic and therapeutic strategies aimed at preventing Aβ generation and oxidative stress may represent an effective approach for AD treatment. A recent paradigm for the treatment of complex diseases such as AD suggests the employment of multifunctional compounds, single chemical entities capable of simultaneously modulating different targets involved in the pathology. In this paper, the “pharmacophores combination” strategy was applied, connecting the main scaffold of the BACE-1 ligand 1 to that of the chalcone 2, as metal chelating pharmacophore, to obtain a small library of compounds. Conjugate 5 emerged as the most interesting derivative, proving to inhibit BACE-1 with low-micromolar potency, and showing neuroprotective effects. In particular, 5 proved to be able to protect from metal-associated oxidative stress by hampering intracellular Cu2+-induced ROS formation without any direct neurotoxic effect.Keywords
This publication has 28 references indexed in Scilit:
- 2015 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2015
- The emergence of designed multiple ligands for neurodegenerative disordersProgress in Neurobiology, 2011
- Myricetin: A Naturally Occurring Regulator of Metal‐Induced Amyloid‐β Aggregation and NeurotoxicityChemBioChem, 2011
- The chemistry of Alzheimer’s diseaseChemical Society Reviews, 2009
- Synthetic strategies of nonpeptidic β‐secretase (BACE1) inhibitorsJournal of Heterocyclic Chemistry, 2009
- Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's diseaseMedicinal Research Reviews, 2008
- Multi-target-Directed Ligands To Combat Neurodegenerative DiseasesJournal of Medicinal Chemistry, 2008
- Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer diseaseNature Medicine, 2003
- Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with InhibitorScience, 2000
- Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive DeclineJAMA, 2000